Scarica l'app Stockscreener
12.27
2.25%
0.27
Evommune Inc Borsa (EVMN) Ultime notizie
Evommune (EVMN) Financial Update: EPS Misses Its Estimate in Latest Trading; Trading Move: Shares Move 10.63% Down in Latest TradingProfit Margin Analysis - vinanet.vn
Evommune (NYSE:EVMN) Trading Down 6.9%Here's What Happened - MarketBeat
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc. (EVMN) Rises 4.12% to $14.65 as Clinical-Stage Biotech Draws Fresh InterestHull Moving Average - vinanet.vn
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune (EVMN) Slips 0.42% to $14.06 as Consolidation Tightens Around Key SupportBreakout Stock Alerts - Vinanet
HC Wainwright Issues Negative Estimate for Evommune Earnings - MarketBeat
Evommune Inc. (EVMN) Holds Steady at $14.07 as Consolidation ContinuesDebt Free Companies - vinanet.vn
Analysts Conflicted on These NA Names: Bob’s Discount Furniture, Inc. (BOBS), Evommune, Inc. (EVMN) and Once Upon a Farm, PBC (OFRM) - The Globe and Mail
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Evommune (NYSE:EVMN) Price Target Cut to $29.00 by Analysts at Royal Bank Of Canada - MarketBeat
Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside - TradingView
Evommune Inc (EVMN) Stock News Today - TradingKey
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum - TradingView
EVMN: Strong cash reserves support key clinical milestones despite higher losses and no Q2 revenue - TradingView
Evommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingView
Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingView
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial - Streetwise Reports
Evommune Inc. (EVMN) Advances 2.76% as Shares Test Key Resistance Near $14Aggressive Growth Picks - vinanet.vn
Evommune Inc. (EVMN) Holds Near $13.09 as Biotech Stock Consolidates Between Key LevelsUndervalued Stocks - dars.gov.et
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
896,700 Shares in Evommune, Inc. $EVMN Purchased by Janus Henderson Group PLC - MarketBeat
HC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN) - MarketBeat
Evommune stock: H.C. Wainwright reiterates Neutral rating By Investing.com - Investing.com India
Evommune stock: H.C. Wainwright reiterates Neutral rating - Investing.com
EVMN Q1 2026 Earnings: Narrower Loss Beats Estimates by 15.6% Amid No RevenuePre-Earnings Drift - vinanet.vn
Evommune doses first patient in migraine prevention trial By Investing.com - Investing.com Nigeria
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis - Yahoo Finance
EVMN Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline AdvancesRevenue Beat Analysis - vinanet.vn
Evommune Inc (EVMN) Institutional Confidence - TradingKey
Evommune Inc (EVMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evommune Inc (EVMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EVMN|Evommune Inc|Price:11.480|Chg%:+0.120 - TradingKey
EVMN|Evommune Inc|Price:11.600|Chg%:+0.350 - TradingKey
Evommune Inc (EVMN) Cash Flow - TradingKey
Evommune Inc (EVMN) Income Statement - TradingKey
Evommune, Inc. Revenue Breakdown – NYSE:EVMN - TradingView
EVMN|Evommune Inc|Price:13.490|Chg%:+0.470 - TradingKey
Evommune Inc (EVMN) Balance Sheet - TradingKey
Evommune Inc (EVMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evommune Inc (EVMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVMN|Evommune Inc|Price:11.360|Chg%:+0.060 - TradingKey
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineFinancial Health Score - po-news-eg.net
Evommune (EVMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Call Transcript - vinanet.vn
Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Surprise Exceeds Expectations Amid Pre-Revenue StageBanking Earnings Report - dars.gov.et
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower Loss Highlights Cost Discipline for Pre-Revenue BiotechBalance Sheet Strength - vinanet.vn
Top Evommune (EVMN) Competitors 2026 - MarketBeat
Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD - TradingView
EVMN Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline for Pre-Revenue BiotechEarnings Forecast Report - Vinanet
Evommune Inc. Q1 2026 Earnings: EPS Beat Exceeds Expectations Amid Pre-Revenue PhaseSurprise Factor Analysis - dars.gov.et
Clear Street Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
If You Invested $1,000 in EVOMMUNE INC (EVMN) - Stock Titan
Kyle Carver Increases Stake in Evommune Inc with Recent Share Pu - GuruFocus
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):